Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up

Tue, 23rd Oct 2012 09:23

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept.ARM Holdings: Investec keeps buy rating and 800p target.Avacta: Panmure Gordon keeps buy rating and 1.75p target.AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept.Babcock: JPMorgan Cazenove ups target from 990p to 1,050p, overweight rating kept.Barclays: Exane BNP Paribas ups target from 330p to 340p, outperform rating kept; HSBC lifts target from 180p to 260p, neutral rating kept.BBA Aviation: Westhouse Securities downgrades to neutral.BP: Jefferies keeps hold rating and 450p target.BP Marsh & Partners: Panmure Gordon ups target from 125p to 130p, buy rating kept.British American Tobacco: Credit Suisse ups target from 3,400p to 3,430p, outperform rating kept.Bullabulling Gold: Westhouse Securities initiates with buy rating and 21p target..Burberry: Deutsche Bank keeps hold rating and 1,275p target.CRH: HSBC downgrades to neutral, target cut from 16p to 15p.Direct Line: Nomura initiates with reduce rating and 174p target.e-Therapeutics: Panmure Gordon keeps buy rating and 73p target.Experian: Jefferies keeps buy rating and 1,060p target; Seymour Pierce keeps reduce rating and 1,000p target.Genel Energy: HSBC downgrades to neutral, target upped from 816p to 830p.Hammerson: Jefferies raises target from 501p to 503p, hold rating kept.Inchcape: Panmure Gordon keeps hold rating and 430p target.Johnson Matthey: UBS cuts target from 2,378p to 2,300p, neutral rating kept.Laird: Investec keeps hold rating and 225p target.Mulberry: Barclays Capital cuts target from 1,600p to 1,250p, equal weight rating kept; Panmure Gordon slashes target from 2,000p to 1,100p, buy rating kept.N Brown: UBS ups target from 285p to 340p, buy rating kept.Premier Foods: Panmure Gordon keeps hold rating and 90p target; Investec puts buy rating and 100p target under review.Redrow: UBS downgrades to neutral, target lifted from 160p to 170p.SDL: Goldman Sachs cuts target from 915p to 820p, buy rating kept.Unilever: Oriel Securities downgrades to hold, target raised from 2,200p to 2,320p.Whitbread: Investec maintains sell rating and 1,650p target; Nomura maintains buy rating and 2,650p target; Panmure Gordon keeps hold rating and 1,994p target; Investec keeps sell rating and 1,650p target.BC
More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.